ClinicalTrials.gg
Not yet recruitingNCT07787481AI\SKUpdated Aug 26, 2026

AI in SK Histopathological Diagnosis

An observational study in Seborrheic Keratoses and Artifical Intelligence, sponsored by Al-Azhar University. Not yet recruiting at 1 site in Egypt. Per ClinicalTrials.gov, last updated 2026-08-26.

Sponsored by Al-Azhar University · Observational

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Retrospective
Enrollment
30
Sex
All
01

Study summary

The aim of this study is to evaluate the diagnostic performance of an Artificial Intelligence (AI) algorithm in the histopathological diagnosis of Seborrheic keratosis compared to Certified Dermatopathologists.

Read the detailed description

Seborrheic keratosis (SK) is one of the most common benign epidermal tumors. Treatment is generally unnecessary, although lesions may be removed because of irritation, pruritus, or cosmetic concerns. SK has several clinical and histological subtypes, including common seborrheic keratosis (CSK), which is more prevalent among Caucasians, and dermatosis papulosa nigra (DPN), which is more common in individuals with Fitzpatrick skin phototypes III and above. Its development is associated mainly with age and genetic predisposition, with possible contribution from ultraviolet radiation. Lesions may occur almost anywhere except the palms and soles, with the face and upper trunk being common sites. Diagnosis is usually clinical but may be supported by dermoscopy or histopathology.

Histologically, SK represents an intraepidermal proliferation of squamous or basaloid cells. The characteristic findings include acanthosis, papillomatosis, hyperkeratosis, keratin cysts, and keratin pseudocysts. Cellular atypia is generally absent, while the amount of melanin and melanocytes varies according to the degree of pigmentation. SK shows considerable clinical and histological variability, which can sometimes make differentiation from other lesions, such as keratoacanthoma and clear cell acanthoma, challenging.

Recent advances in digital pathology and artificial intelligence (AI) have created new opportunities for diagnostic support in dermatopathology. AI aims to mimic aspects of human intelligence, while machine learning enables computers to identify patterns from data. Deep learning, neural networks, and convolutional neural networks (CNNs) are particularly important in image analysis. AI in dermatopathology has evolved from early text-based systems such as TEGUMENT, introduced in 1987, to modern systems capable of directly analyzing digital pathology images. Although widespread clinical implementation is still developing, AI has potential applications in diagnosis, triage, education, and research and requires collaboration between dermatopathologists, pathologists, clinicians, engineers, and data scientists.

Study Methodology

H\&E-stained glass slides will be collected from the Al-Hussein dermatopathology archive, covering the period from 2010 to 2019. A panel of certified dermatopathologists will evaluate the slides. Their diagnoses will serve as the gold standard against which the AI results will be compared.

The slides will be digitized using a Leica Aperio GT450 scanner at 40× magnification. Before scanning, slides will be cleaned and assessed for adequate staining, proper coverslipping, and absence of artifacts such as air bubbles, tissue folds, or debris. The scanner can accommodate 15 racks with 30 slides per rack, for a total of 450 slides per run, with approximately 1.5-2 minutes required to scan each slide.

Whole Slide Images (WSIs) will be generated and stored in SVS format, with individual file sizes typically ranging from approximately 500 MB to 2 GB. The digital slides will then undergo quality control using Aperio ImageScope to ensure adequate focus, clarity, and complete tissue capture. Suboptimal slides will be rescanned. The images will subsequently be transferred to an external hard drive for storage and backup before being uploaded to the HistoGPT cloud platform for AI analysis.

HistoGPT Analysis

The WSIs will be analyzed using HistoGPT, a Vision-Language Model for Digital Pathology. Because WSIs are extremely large, they are first divided into smaller image patches or tiles, typically 256×256 or 512×512 pixels. Tissue detection is then performed to exclude background areas and focus the analysis on the tissue.

HistoGPT uses a Vision Transformer (ViT) and a Hierarchical Vision Transformer (HiViT) to extract histological features at multiple scales. This allows the model to identify both microscopic features, such as cellular atypia and mitotic figures, and larger architectural patterns, such as symmetry, circumscription, and infiltrative growth.

Through attention mechanisms, the model can also establish relationships between spatially distant areas of the slide and recognize the importance of tissue organization and anatomical location. Its cross-modal alignment allows visual histological features to be associated with terminology used in pathology reports, enabling recognition of concepts such as keratin pearls, clefting, and solar elastosis.

Finally, the language component of HistoGPT generates a structured pathology report, potentially including a microscopic description, differential diagnosis, and final diagnosis. The AI-generated reports will be compared with the reports and diagnoses produced by the dermatopathology experts, and the time required for the diagnostic process will also be assessed.

Statistical Analysis

The collected data will be analyzed using SPSS version 26.0 or R programming. A p-value \< 0.05 will be considered statistically significant. Overall, the study aims to evaluate the diagnostic performance and time efficiency of HistoGPT in dermatopathology by comparing its findings with expert dermatopathologists serving as the gold standard.

02

Conditions studied

  • Seborrheic Keratoses
  • Artifical Intelligence

Browse trials for

03

In context

Keratosis, Seborrheic

29 studies on the registry are indexed under Keratosis, Seborrheic; 3 are open to participants now.

Browse Keratosis, Seborrheic studies →

Lead sponsor

Al-Azhar University is the lead sponsor of 531 studies on the registry; 172 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Seborrheic keratosis H\&E stained glass slides from the pathology archive of Al-hussein dermatopathology unit.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Histopathological slides diagnosed as Seborrheic keratosis.
  2. Slides with adequate staining and preservation allowing clear visualization of histopathological features.

Exclusion criteria

Exclusion Criteria:

  1. Slides with poor staining quality or significant artifacts interfering with histopathological interpretation.
  2. Slides that were damaged, faded, or inadequately preserved.
  3. Cases with uncertain or inconclusive original diagnoses.
  4. Slides that could not be successfully digitized due to technical limitations ex: very short or too long slides.
05

Study design

Observational model
Other
Time perspective
Retrospective
Enrollment
30 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Interventions

  • OtherThis study doesn't include an intervention.

    This study doesn't include an intervention.

06

What researchers measure

Primary outcomes

  1. The accuracy of the artificial intelligence algorithm in histopathological diagnosis of seborrheic keratosis evaluated mainly by sensitivity and specificity.

    Time frame: 1 year

07

Study locations

1 site
  • Faculty of medicine, Al-Azhar University boys branch in Cairo
    Cairo, Egypt
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Oct 2026; primary completion for Oct 2027, 12 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 23, 2026
First posted
Aug 26, 2026
StartEst.
Oct 1, 2026
Primary completionEst.
Oct 1, 2027
CompletionEst.
Dec 1, 2027
Last update
Aug 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07787481
Responsible party
Hebatullah Fouad Mahmoud Elkerm (Resident dermatologist, Al-Azhar University) — Principal investigator
First posted
Aug 26, 2026
Start date
Oct 1, 2026 (estimated)
Primary completion
Oct 1, 2027 (estimated)
Completion
Dec 1, 2027 (estimated)
Last update
Aug 26, 2026

Study contacts

Hebatullah Fouad Elkerm
Contact
hebaf.alkerm@gmail.com
+201111075736

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion